Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Abstract Text:

Elizabeth B Fryar-Tita,Jharna R Das,J H Davis,J A Desoto,Sidney Green,William M Southerland,Donnell Bowen,

BACKGROUND: Breast cancer patients are at increased risk of osteoporosis. Contributing factors include age and/or chemotherapy. The selective estrogen modulator, raloxifene (RAL), effective in the prevention of breast cancer and approved for the treatment and prevention of osteoporosis, may prove beneficial in current breast cancer treatment modules. The purpose of this study was to evaluate RAL in combination with 5-fluorouracil (5-FU) and trimetrexate (TMX) to determine the most effective sequence in which to administer these cell cycle specific agents while taking into consideration the cellular mechanism of action. The goal was to maintain cytotoxicity to breast cancer cells and capitalize on the selective estrogen receptor modulatory effects of RAL. MATERIALS AND METHODS: MCF-7 cells were exposed to (i) TMX, 5-FU or RAL alone, or (ii) RAL 24 h prior to 5-FU followed 2 h later by TMX, or (iii) 5-FU 2 h prior to TMX followed 24 h later by RAL. The cell viability was determined using the Quick Cell Proliferation Assay. RESULTS: The growth rate of MCF- 7 cells exposed to early RAL was 68.25 +/- 4.11% that of the control, however, late RAL exposure produced a growth of 34.75 +/- 4.79% that of the control. Late RAL maintained the cytotoxicity of the regimen. The findings were further supported by cell flow cytometry and Western blot analysis data. CONCLUSION: RAL given prior to 5-FU/TMX significantly compromised cytotoxicity to breast cancer cells.

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Publishing Authors By Initials

EB Fryar-Tita,JR Das,JH Davis,JA Desoto,S Green,WM Southerland,D Bowen,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines: trimetrexate research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines: trimetrexate research

PUBMED ID PMID:

MEDLINE DATE:

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Anticancer research

VOLUME: 27

Page Numbers: 1393-9

Journal Abbreviation: Anticancer Res.

ISSN: 0250-7005

DAY: 3

MONTH: 12

YEAR: 2007

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8102988

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Keywords Mesh Terms:

KEYWORDS: Trimetrexate

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Information

Substance Name: Raloxifene

Registry Number: 84449-90-1

Grant and Affiliation Information for Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

AFFILIATION: Department of Environmental Sciences and Engineering, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Country: Greece

AGENCY: United States NCRR

GRANT: G12RR003048-18

ACRONYM: RR

MEDLINETA: Anticancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies Related Publications

• Acute onset left hemiparesis and facial droop in a 37 year old soccer player: 1123: june 1 3:15 PM - 3:35 PM.
• C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.
• Chain of custody as an organizing framework in seafood risk reduction.
• Complex palliative care and transition: a case review.
• Decontaminable surfaces for millicurie-level laboratories.
• Determination of cell colony formation in a high-content screening assay.
• Duplications involving int22h-1 of the factor VIII gene: a cause for concern in genetic testing for hemophilia A?
• Dynamics of passive immunity to West Nile virus in domestic chickens (Gallus gallus domesticus).
• Electron-cytochemical localization of acid phosphatase activity in the digestive caeca of the desert locust.
• Failure to induce an antiviral state in preimplantation bovine embryos treated with interferon.
• Health impact assessments in London: assessing the London Mayoral strategies.
• Increases in amphetamine-like discriminative stimulus effects of the abused inhalant toluene in mice.
• MR angiography versus CT angiography in the evaluation of neurovascular disease.
• Methods and normal values for echocardiography in adult dairy cattle.
• Photoelectron spectroscopy of hydrated adenine anions.
• Predictors of self-referral into a cancer genetics registry.
• Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
• Results of a randomized study of telephone versus in-person breast cancer risk counseling.
• Salivary glucosyltransferase B as a possible marker for caries activity.
• Self-rated breast cancer risk among women reporting a first-degree family history of breast cancer on office screening questionnaires in routine medical care: the role of physician-delivered risk feedback.
• Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
• Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
• Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis.
• The cancer worry chart: a single-item screening measure of worry about developing breast cancer.
• The correction of leg-length discrepancy after treatment in developmental dysplasia of the hip by using a percutaneous epiphysiodesis.
• The effects of methyltestosteone on reproductive function in male greyhounds.
• The effects of prostalene and alfaprostol as uterine myotonics, and the effect on postpartum pregnancy rate in the mare following daily treatment with prostalene.
• The impact of HIV-related interventions on HIV risk behavior in a community sample of African American crack cocaine users.
• The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
• Use of the statistical properties of the wavelet-transform coefficients for optimization of integration time in Fourier transform spectrometry.